Skip to main content

Articles

Page 1 of 75

  1. Studies have shown that CCR7, an important inflammatory factor, can promote the proliferation and metastasis of oral squamous cell carcinoma (OSCC), but its role in the tumor microenvironment (TME) remains unc...

    Authors: Zengxu Wang, Keith L. Kirkwood, Yao Wang, Weidong Du, Shanfeng Lin, Wanhang Zhou, Cong Yan, Jiaxing Gao, Zhenning Li, Changfu Sun and Fayu Liu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:94
  2. Based on the established role of cancer-stroma cross-talk in tumor growth, progression and chemoresistance, targeting interactions between tumor cells and their stroma provides new therapeutic approaches. Dual...

    Authors: Simona Camorani, Alessandra Caliendo, Elena Morrone, Lisa Agnello, Matteo Martini, Monica Cantile, Margherita Cerrone, Antonella Zannetti, Massimo La Deda, Monica Fedele, Loredana Ricciardi and Laura Cerchia
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:92
  3. Pancreatic cancer (PC) is a highly malignant gastrointestinal tumor, which is characterized by difficulties in early diagnosis, early metastasis, limited therapeutic response and a grim prognosis. Therefore, i...

    Authors: Xiaobin Fei, Changhao Zhu, Peng Liu, Songbai Liu, Likun Ren, Rishang Lu, Junyi Hou, Yongjia Gao, Xing Wang and Yaozhen Pan
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:91
  4. Ropivacaine, a local anesthetic, exhibits anti-tumor effects in various cancer types. However, its specific functions and the molecular mechanisms involved in breast cancer cell stemness remain elusive.

    Authors: Lin Ding, Hui Jiang, Qiangwei Li, Qiushuang Li, Tian-Tian Zhang, Limeng Shang, Bin Xie, Yaling Zhu, Keshuo Ding, Xuanming Shi, Tao Zhu and Yong Zhu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:90
  5. The evasion of the immune response by tumor cells through programmed death-ligand 1 (PD-L1) has been identified as a factor contributing to resistance to radioimmunotherapy in lung cancer patients. However, th...

    Authors: Zixuan Li, Huichan Xue, Jinsong Li, Zhikun Zheng, Zhiwei Liu, Xiaorong Dong, Hongbo Wang, Jing Chen and Shuangbing Xu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:89
  6. This study explores the repurposing of Auranofin (AF), an anti-rheumatic drug, for treating non-small cell lung cancer (NSCLC) adenocarcinoma and pancreatic ductal adenocarcinoma (PDAC). Drug repurposing in on...

    Authors: Christophe Deben, Laurie Freire Boullosa, Felicia Rodrigues Fortes, Edgar Cardenas De La Hoz, Maxim Le Compte, Sofie Seghers, Marc Peeters, Steve Vanlanduit, Abraham Lin, Krijn K. Dijkstra, Paul Van Schil, Jeroen M. H. Hendriks, Hans Prenen, Geert Roeyen, Filip Lardon and Evelien Smits
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:88
  7. We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs). The present study aimed to assess the breadth of ...

    Authors: Beatrice Cavalluzzo, Marie Christine Viuff, Siri Amanda Tvingsholm, Concetta Ragone, Carmen Manolio, Angela Mauriello, Franco M. Buonaguro, Maria Lina Tornesello, Francesco Izzo, Alessandro Morabito, Sine Reker Hadrup, Maria Tagliamonte and Luigi Buonaguro
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:87
  8. In clear cell renal cell carcinoma (ccRCC), first-line treatment combines nivolumab (anti-PD-1) and ipilimumab (anti-CTLA4), yielding long-term remissions but with only a 40% success rate. Our study explored t...

    Authors: Christopher Montemagno, Arnaud Jacquel, Charlotte Pandiani, Olivia Rastoin, Rosie Dawaliby, Thomas Schmitt, Maxence Bourgoin, Héliciane Palenzuela, Anne-Laure Rossi, Damien Ambrosetti, Jerome Durivault, Frederic Luciano, Delphine Borchiellini, Julie Le Du, Leticia Christina Pires Gonçalves, Patrick Auberger…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:86
  9. Anaplastic thyroid cancer (ATC) is the most aggressive thyroid cancer. Despite advances in tissue culture techniques, a robust model for ATC spheroid culture is yet to be developed. In this study, we created a...

    Authors: Jiangnan Hu, Kaili Liu, Chandrayee Ghosh, Tejinder Pal Khaket, Helen Shih and Electron Kebebew
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:85
  10. How platelets interact with and influence the tumor microenvironment (TME) remains poorly characterized.

    Authors: Ophélie Le Chapelain, Soumaya Jadoui, Angèle Gros, Samir Barbaria, Keltouma Benmeziane, Véronique Ollivier, Sébastien Dupont, Mialitiana Solo Nomenjanahary, Sabrina Mavouna, Jasmina Rogozarski, Marie-Anne Mawhin, Giuseppina Caligiuri, Sandrine Delbosc, Françoise Porteu, Bernhard Nieswandt, Pierre H Mangin…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:84
  11. Tumor angiogenesis inhibitors have been applied for non-small cell lung cancer (NSCLC) therapy. However, the drug resistance hinders their further development. Intercellular crosstalk between lung cancer cells...

    Authors: Xueping Lei, Zhan Li, Manting Huang, Lijuan Huang, Yong Huang, Sha Lv, Weisong Zhang, Zhuowen Chen, Yuanyu Ke, Songpei Li, Jingfei Chen, Xiangyu Yang, Qiudi Deng, Junshan Liu and Xiyong Yu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:83
  12. The paradigm of non-small cell lung cancer (NSCLC) treatment has been profoundly influenced by the development of immune checkpoint inhibitors (ICI), but the range of clinical responses observed among patients...

    Authors: Yo-Ting Tsai, Jeffrey Schlom and Renee N. Donahue
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:82
  13. Immune-checkpoint inhibitors (ICIs) have showed unprecedent efficacy in the treatment of patients with advanced non-small cell lung cancer (NSCLC). However, not all patients manifest clinical benefit due to th...

    Authors: Diego de Miguel‑Perez, Murat Ak, Priyadarshini Mamindla, Alessandro Russo, Serafettin Zenkin, Nursima Ak, Vishal Peddagangireddy, Luis Lara‑Mejia, Muthukumar Gunasekaran, Andres F. Cardona, Aung Naing, Fred R. Hirsch, Oscar Arrieta, Rivka R. Colen and Christian Rolfo
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:81
  14. Authors: Yu-Jiao Zhou, Min-Li Yang, Xin He, Hui-Ying Gu, Ji-Hua Ren, Sheng-Tao Cheng, Zhou Fu, Zhen-Zhen Zhang and Juan Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:80

    The original article was published in Journal of Experimental & Clinical Cancer Research 2024 43:45

  15. Acute myeloid leukemia (AML) with biallelic (CEBPAbi) as well as single mutations located in the bZIP region is associated with a favorable prognosis, but the underlying mechanisms are still unclear. Here, we pro...

    Authors: Mengbao Du, Mowang Wang, Meng Liu, Shan Fu, Yu Lin, Yankun Huo, Jian Yu, Xiaohong Yu, Chong Wang, Haowen Xiao and Limengmeng Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:79
  16. The DNA damage response (DDR) is a physiological network preventing malignant transformation, e.g. by halting cell cycle progression upon DNA damage detection and promoting DNA repair. Glioblastoma are incurab...

    Authors: Bianca Walter, Sophie Hirsch, Laurence Kuhlburger, Aaron Stahl, Leonard Schnabel, Silas Wisser, Lara A. Haeusser, Foteini Tsiami, Sarah Plöger, Narges Aghaallaei, Advaita M Dick, Julia Skokowa, Christian Schmees, Markus Templin, Katja Schenke-Layland, Marcos Tatagiba…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:77
  17. While T cell-activating immunotherapies against recurrent head and neck squamous cell carcinoma (HNSCC) have shown impressive results in clinical trials, they are often ineffective in the majority of patients....

    Authors: Fan Yang, Chenyang Yuan, Fanghui Chen, Zhaohui S. Qin, Nicole C. Schmitt, Gregory B. Lesinski, Nabil F. Saba and Yong Teng
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:76
  18. Breast Cancer (BC) can be classified, due to its heterogeneity, into multiple subtypes that differ for prognosis and clinical management. Notably, triple negative breast cancer (TNBC) – the most aggressive BC ...

    Authors: Sara Iachettini, Irene Terrenato, Manuela Porru, Serena Di Vito, Angela Rizzo, Carmen D’Angelo, Eleonora Petti, Roberto Dinami, Carmen Maresca, Anna Di Benedetto, Aldo Palange, Antonino Mulè, Angela Santoro, Antonella Palazzo, Paola Fuso, Antonella Stoppacciaro…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:75
  19. Glutamine metabolism plays a pivotal role in cancer progression, immune cell function, and the modulation of the tumor microenvironment. Dysregulated glutamine metabolism has been implicated in cancer developm...

    Authors: Bolin Wang, Jinli Pei, Shengnan Xu, Jie Liu and Jinming Yu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:74

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2024 43:93

  20. The TGF-β signalling pathway is intricately associated with the progression of glioblastoma (GBM). The objective of this study was to examine the role of circRNAs in the TGF-β signalling pathway.

    Authors: Yuhang Wang, Binbin Wang, Wenping Cao and Xiupeng Xu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:73
  21. The paucity of reliable biomarkers for predicting immunotherapy efficacy in patients with advanced hepatocellular carcinoma (HCC) has emerged as a burgeoning concern with the expanding use of immunotherapy. Th...

    Authors: Xiaoxuan Tu, Longxian Chen, Yi Zheng, Chenglin Mu, Zhiwei Zhang, Feiyu Wang, Yiqing Ren, Yingxin Duan, Hangyu Zhang, Zhou Tong, Lulu Liu, Xunqi Sun, Peng Zhao, Lie Wang, Xinhua Feng, Weijia Fang…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:72
  22. A firm link between endoplasmic reticulum (ER) stress and tumors has been wildly reported. Endoplasmic reticulum oxidoreductase 1 alpha (ERO1α), an ER-resident thiol oxidoreductase, is confirmed to be highly u...

    Authors: Peng Chen, Amit Sharma, Hans Weiher and Ingo G.H. Schmidt-Wolf
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:71
  23. The combination of radiotherapy and immunotherapy (immunoradiotherapy) has been increasingly used for treating a wide range of cancers. However, some tumors are resistant to immunoradiotherapy. We have previou...

    Authors: Yun Hu, Alexey Revenko, Hampartsoum Barsoumian, Genevieve Bertolet, Natalie Wall Fowlkes, Hadi Maazi, Morgan Maureen Green, Kewen He, Duygu Sezen, Tiffany A. Voss, Claudia S Kettlun Leyton, Fatemeh Masrorpour, Zahid Rafiq, Nahum Puebla-Osorio, Carola Leuschner, Robert MacLeod…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:70
  24. Head and neck squamous carcinoma (HNSCC) is known for its high aggressiveness and susceptibility to cervical lymph node metastasis, which greatly contributes to its poor prognosis. During tumorigenesis, many t...

    Authors: Hongshi Cai, Jianfeng Liang, Yaoqi Jiang, Ziyi Wang, Hongyu Li, Wenjin Wang, Cheng Wang and Jinsong Hou
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:69
  25. Proteasome inhibitors (PIs) are one of the most important classes of drugs for the treatment of multiple myeloma (MM). However, almost all patients with MM develop PI resistance, resulting in therapeutic failu...

    Authors: Xiaobin Wang, Yingqing Shi, Hua Shi, Xiaoyu Liu, Aijun Liao, Zhuogang Liu, Robert Z. Orlowski, Rui Zhang and Huihan Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:68
  26. Docetaxel resistance represents a significant obstacle in the treatment of prostate cancer. The intricate interplay between cytokine signalling pathways and transcriptional control mechanisms in cancer cells c...

    Authors: Bisheng Cheng, Lingfeng Li, Tianlong Luo, Qiong Wang, Yong Luo, Shoumin Bai, Kaiwen Li, Yiming Lai and Hai Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:67
  27. CRISPR/Cas9 system to treat human-related diseases has achieved significant results and, even if its potential application in cancer research is improving, the application of this approach in clinical practice...

    Authors: M Caforio, S Iacovelli, C Quintarelli, F Locatelli and Valentina Folgiero
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:66
  28. Cingulin (CGN) is a pivotal cytoskeletal adaptor protein located at tight junctions. This study investigates the link between CGN mutation and increased cancer susceptibility through genetic and mechanistic analy...

    Authors: Yi-Ting Huang, Ya-Ting Hsu, Pei-Ying Wu, Yu-Min Yeh, Peng-Chan Lin, Keng-Fu Hsu and Meng-Ru Shen
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:65
  29. Colorectal cancer (CRC) is a heterogenous malignancy underpinned by dysregulation of cellular signaling pathways. Previous literature has implicated aberrant JAK/STAT3 signal transduction in the development an...

    Authors: Kathryn A. F. Pennel, Phimmada Hatthakarnkul, Colin S. Wood, Guang-Yu Lian, Sara S. F. Al-Badran, Jean A. Quinn, Assya Legrini, Jitwadee Inthagard, Peter G. Alexander, Hester van Wyk, Ahmad Kurniawan, Umar Hashmi, Michael A. Gillespie, Megan Mills, Aula Ammar, Jennifer Hay…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:64
  30. Lung cancer is one of the most common tumors in the world, and metastasis is one of the major causes of tumor-related death in lung cancer patients. Tumor-associated macrophages (TAMs) are a major component of...

    Authors: Zhengyang Hu, Qihai Sui, Xing Jin, Guangyao Shan, Yiwei Huang, Yanjun Yi, Dejun Zeng, Mengnan Zhao, Cheng Zhan, Qun Wang, Zongwu Lin, Tao Lu and Zhencong Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:63
  31. In recent years, the development of adjunctive therapeutic hyperthermia for cancer therapy has received considerable attention. However, the mechanisms underlying hyperthermia resistance are still poorly under...

    Authors: Tao-Yan Lin, Jun-Shuang Jia, Wei-Ren Luo, Xiao-Lin Lin, Sheng-Jun Xiao, Jie Yang, Jia-Wei Xia, Chen Zhou, Zhi-Hao Zhou, Shu-Jun Lin, Qi-Wen Li, Zhi-Zhi Yang, Ye Lei, Wen-Qing Yang, Hong-Fen Shen, Shi-Hao Huang…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:62
  32. The inability to predict treatment response of colorectal cancer patients results in unnecessary toxicity, decreased efficacy and survival. Response testing on patient-derived organoids (PDOs) is a promising b...

    Authors: Lidwien P. Smabers, Emerens Wensink, Carla S. Verissimo, Esmee Koedoot, Katerina-Chara Pitsa, Maarten A. Huismans, Celia Higuera Barón, Mayke Doorn, Liselot B. Valkenburg-van Iersel, Geert A. Cirkel, Anneta Brousali, René Overmeer, Miriam Koopman, Manon N. Braat, Bas Penning de Vries, Sjoerd G. Elias…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:61
  33. Cancer cells can overexpress CD47, an innate immune checkpoint that prevents phagocytosis upon interaction with signal regulatory protein alpha (SIRPα) expressed in macrophages and other myeloid cells. Several...

    Authors: Maria Gracia-Hernandez, Ashutosh S. Yende, Nithya Gajendran, Zubaydah Alahmadi, Xintang Li, Zuleima Munoz, Karen Tan, Satish Noonepalle, Maho Shibata and Alejandro Villagra
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:60
  34. Hematological metastasis has been recognized as a crucial factor contributing to the high rates of metastasis and mortality observed in colorectal cancer (CRC). Notably, exosomes derived from cancer cells part...

    Authors: Keyu Li, Wenhua Xue, Zhihua Lu, Suo Wang, Jiayao Zheng, Kuangyi Lu, Ming Li, Yang Zong, Feng Xu, Jiamin Dai, Yang Yang and Jinbing Sun
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:59
  35. Advanced prostate cancer (PC) is characterized by insensitivity to androgen deprivation therapy and chemotherapy, resulting in poor outcome for most patients. Thus, advanced PC urgently needs novel therapeutic...

    Authors: Chiara Naro, Ambra Antonioni, Vanessa Medici, Cinzia Caggiano, Ariane Jolly, Pierre de la Grange, Pamela Bielli, Maria Paola Paronetto and Claudio Sette
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:58
  36. Hypoxia in solid tumors is an important source of chemoresistance that can determine poor patient prognosis. Such chemoresistance relies on the presence of cancer stem cells (CSCs), and hypoxia promotes their ...

    Authors: Sandra Muñoz-Galván, Eva M. Verdugo-Sivianes, José M. Santos-Pereira, Purificación Estevez-García and Amancio Carnero
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:57
  37. Ovarian cancer (OC) is a prevalent malignancy in the female reproductive system, and developing effective targeted therapies for this disease remains challenging. The aim of this study was to use clinically-re...

    Authors: Weisong Li, Kai Zhang, Wenjun Wang, Yuanyuan Liu, Jianming Huang, Meihong Zheng, Ling Li, Xinyu Zhang, Minjuan Xu, Guofang Chen, Liefeng Wang and Shuyong Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:56
  38. Authors: Wenwei Liao, Jinpeng Du, Lian Li, Xianquan Wu, Xing Chen, Qingbo Feng, Lin Xu, Xiangzheng Chen, Mingheng Liao, Jiwei Huang, Kefei Yuan and Yong Zeng
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:55

    The original article was published in Journal of Experimental & Clinical Cancer Research 2023 42:125

  39. LATS1/2 are frequently mutated and down-regulated in endometrial cancer (EC), but the contributions of LATS1/2 in EC progression remains unclear. Impaired antigen presentation due to mutations or downregulatio...

    Authors: Qianlan Yang, Zehen Lv, Mengfei Wang, Mengwen Kong, Cheng Zhong, Kun Gao and Xiaoping Wan
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:54
  40. Esophageal cancer is one of the 10 most common cancers worldwide and its incidence is dramatically increasing. Despite some improvements, the current surveillance protocol with white light endoscopy and random...

    Authors: Sabrina Marcazzan, Marcos J. Braz Carvalho, Nghia T. Nguyen, Julia Strangmann, Julia Slotta-Huspenina, Anna Tenditnaya, Markus Tschurtschenthaler, Jonas Rieder, Andrea Proaño-Vasco, Vasilis Ntziachristos, Katja Steiger, Dimitris Gorpas, Michael Quante and Susanne Kossatz
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:53
  41. Osteosarcoma (OS) is one of most commonly diagnosed bone cancer. Circular RNAs (circRNAs) are a class of highly stable non-coding RNA, the majority of which have not been characterized functionally. The underl...

    Authors: Ying Zhang, Zhaoyong Liu, Zhigang Zhong, Yanchen Ji, Huancheng Guo, Weidong Wang and Chuangzhen Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:52
  42. Immune checkpoint blockade (ICB) is widely considered to exert long-term treatment benefits by activating antitumor immunity. However, many cancer patients show poor clinical responses to ICB due in part to th...

    Authors: Baoyuan Zhang, Ning Li, Jiaming Gao, Yuxi Zhao, Jun Jiang, Shuang Xie, Cuiping Zhang, Qingyu Zhang, Leo Liu, Zaiqi Wang, Dongmei Ji, Lingying Wu and Ruibao Ren
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:51
  43. Phosphatase and tensin homolog deleted on chromosome ten (PTEN) serves as a powerful tumor suppressor, and has been found to be downregulated in human bladder cancer (BC) tissues. Despite this observation, the...

    Authors: Tengda Li, Maowen Huang, Ning Sun, Xiaohui Hua, Ruifan Chen, Qipeng Xie, Shirui Huang, Mengxiang Du, Yazhen Zhao, Qianqian Lin, Jiheng Xu, Xiaoyun Han, Yunping Zhao, Zhongxian Tian, Yu Zhang, Wei Chen…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:50
  44. SMC1A is a subunit of the cohesin complex that participates in many DNA- and chromosome-related biological processes. Previous studies have established that SMC1A is involved in cancer development and in particul...

    Authors: Maddalena Di Nardo, Simonetta Astigiano, Silvia Baldari, Maria Michela Pallotta, Giovanni Porta, Simona Pigozzi, Annalisa Antonini, Laura Emionite, Annalisa Frattini, Roberto Valli, Gabriele Toietta, Silvia Soddu and Antonio Musio
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:49
  45. In tumor therapeutics, the transition from conventional cytotoxic drugs to targeted molecular therapies, such as those targeting receptor tyrosine kinases, has been pivotal. Despite this progress, the clinical...

    Authors: Moksada Regmi, Yingjie Wang, Weihai Liu, Yuwei Dai, Shikun Liu, Ke Ma, Guozhong Lin, Jun Yang, Hongyi Liu, Jian Wu and Chenlong Yang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:47
  46. Nasopharyngeal carcinoma (NPC) poses a significant health burden in specific regions of Asia, and some of NPC patients have bone metastases at the time of initial diagnosis. Bone metastasis can cause pathologi...

    Authors: Kaifan Yang, Yanjun Hu, Yuanyuan Feng, Kaiqun Li, Ziyan Zhu, Shuyi Liu, Yanling Lin and Bin Yu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:46
  47. Metastasis is one of the leading cause contributes to treatment failure and poor prognosis of hepatocellular carcinoma (HCC) patients. The underlying mechanism of HCC metastasis remains to be determined. Altho...

    Authors: Yu-Jiao Zhou, Min-Li Yang, Xin He, Hui-Ying Gu, Ji-Hua Ren, Sheng-Tao Cheng, Zhou Fu, Zhen-Zhen Zhang and Juan Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:45
  48. m6A modification is currently recognized as a major driver of RNA function that maintains cancer cell homeostasis. Long non-coding (Lnc) RNAs control cell proliferation and play an important role in the occurr...

    Authors: Ke Chen, Jingcheng Zhang, Lei Meng, Lingshang Kong, Ming Lu, Zhengguang Wang and Wenbin Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:44

Annual Journal Metrics

  • 2022 Citation Impact
    11.3 - 2-year Impact Factor
    11.5 - 5-year Impact Factor
    1.870 - SNIP (Source Normalized Impact per Paper)
    2.413 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    100 days submission to accept (Median)

    2023 Usage 
    3,003,080 downloads
    3,022 Altmetric mentions